Landscapes / Targets
DLL3
15 drugs act on DLL3, in 55 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs15
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Amgen · Public AMGN |
Approved | 24 Sep 2027Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 24 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Extensive Stage Small Cell Lung Cancer, Small Cell Lung Cancer and 7 more | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Neuroendocrine Carcinoma and 5 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Boehringer Ingelheim · Private |
Phase 3 | 17 Dec 2027Phase 2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 17 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms and 13 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Merck & Co. · Public MRK |
Phase 3 | 28 Jan 2028Phase 1/2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 28 Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Small-Cell Lung Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC and 2 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Sep 2028Phase 1/2 trial completes | |||
| Next date | Sep 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jul 2029Phase 1/2 trial completes | |||
| Next date | Jul 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Small-cell Lung Cancer, Neuroendocrine Carcinomas | ||||
| Open drug page | |||||
— |
Phase 1/2 | 3 Mar 2031Phase 1/2 trial completes | |||
| Next date | 3 Mar 2031 · Phase 1/2 trial completes | ||||
| Also tested for | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
AbbVie · Public ABBV |
Phase 2 | Dec 2031Phase 2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Dec 2031 · Phase 2 trial completes | ||||
| Also tested for | Extensive Stage-Small Cell Lung Cancer (ES-SCLC) | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Dec 2027Phase 1 trial completes | |||
| Next date | 1 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma), High Grade Glioma (III or IV) and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2027Phase 1 trial completes | |||
| Next date | Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung | ||||
| Open drug page | |||||
— |
Phase 1 | Mar 2028Phase 1 trial completes | |||
| Next date | Mar 2028 · Phase 1 trial completes | ||||
| Also tested for | Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | 29 Aug 2031Phase 1 trial completes | |||
| Next date | 29 Aug 2031 · Phase 1 trial completes | ||||
| Also tested for | Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung and 9 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 15 of 15 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026